126 related articles for article (PubMed ID: 20815108)
1. Trial results finally show potential for microbicidal HIV gel.
Mohammadi D
Lancet Infect Dis; 2010 Sep; 10(9):587. PubMed ID: 20815108
[No Abstract] [Full Text] [Related]
2. Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness.
Kashuba AD; Gengiah TN; Werner L; Yang KH; White NR; Karim QA; Abdool Karim SS
J Acquir Immune Defic Syndr; 2015 Jul; 69(3):264-9. PubMed ID: 26181703
[TBL] [Abstract][Full Text] [Related]
3. Tenofovir: a pill to prevent HIV?
Bonn D
Lancet Infect Dis; 2005 Feb; 5(2):78. PubMed ID: 15702509
[No Abstract] [Full Text] [Related]
4. Sensitive tenofovir resistance screening of HIV-1 from the genital and blood compartments of women with breakthrough infections in the CAPRISA 004 tenofovir gel trial.
Wei X; Hunt G; Abdool Karim SS; Naranbhai V; Sibeko S; Abdool Karim Q; Li JF; Kashuba AD; Werner L; Passmore JA; Morris L; Heneine W; Johnson JA
J Infect Dis; 2014 Jun; 209(12):1916-20. PubMed ID: 24436453
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of patients with initial early virologic failure after being treated with once-daily tenofovir/abacavir/lamivudine.
Khanlou H; Farthing C
AIDS Patient Care STDS; 2006 Sep; 20(9):604-5. PubMed ID: 16987045
[No Abstract] [Full Text] [Related]
6. A second chance for microbicides.
Baleta A
Lancet; 2007 Jul; 370(9581):17-8. PubMed ID: 17632853
[No Abstract] [Full Text] [Related]
7. Determination of kidney function before tenofovir initiation: four-fold difference in need of tenofovir dose reduction depending on method used.
van Griensven J; Sopheak T; Koole O; Verpooten GA; Lynen L
J Acquir Immune Defic Syndr; 2011 Jun; 57(2):e21-3. PubMed ID: 21709448
[No Abstract] [Full Text] [Related]
8. Report from the 17th Conference on Retroviruses and Opportunistic Infections. Randomized studies of once-daily darunavir and tenofovir/FTC + nevirapine.
Sax PE
J Watch AIDS Clin Care; 2010 Apr; 22(4):33-4. PubMed ID: 20480932
[No Abstract] [Full Text] [Related]
9. Antiretroviral vaginal gel shows promise against HIV.
Baleta A
Lancet; 2010 Jul; 376(9738):320. PubMed ID: 20681062
[No Abstract] [Full Text] [Related]
10. Impact of Tenofovir gel as a PrEP on HIV infection: a mathematical model.
Rahman SM; Vaidya NK; Zou X
J Theor Biol; 2014 Apr; 347():151-9. PubMed ID: 24380779
[TBL] [Abstract][Full Text] [Related]
11. Tenofovir in HIV-infected children. Antiretroviral efficacy, but beware of adverse effects on bone and the kidneys.
Prescrire Int; 2014 May; 23(149):124-5. PubMed ID: 24926511
[TBL] [Abstract][Full Text] [Related]
12. Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa.
Williams BG; Abdool Karim SS; Karim QA; Gouws E
J Acquir Immune Defic Syndr; 2011 Oct; 58(2):207-10. PubMed ID: 21654503
[TBL] [Abstract][Full Text] [Related]
13. Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting.
Calcagno A; Bonora S; Tettoni MC; D'Avolio A; Perri GD; Lanzafame M; Penco G
J Acquir Immune Defic Syndr; 2009 Nov; 52(3):431-2. PubMed ID: 19858926
[No Abstract] [Full Text] [Related]
14. HIV transmission may be prevented by intravaginal tenofovir ring.
Parks L
Future Med Chem; 2012 Dec; 4(18):2239. PubMed ID: 23359902
[No Abstract] [Full Text] [Related]
15. Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial.
Mansoor LE; Abdool Karim Q; Mngadi KT; Dlamini S; Montague C; Nkomonde N; Mvandaba N; Baxter C; Gengiah TN; Samsunder N; Dawood H; Grobler A; Frohlich JA; Abdool Karim SS
Trials; 2014 Dec; 15():496. PubMed ID: 25527071
[TBL] [Abstract][Full Text] [Related]
16. [Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV].
Bayonne Kombo ES; Gathse A
Med Mal Infect; 2013 Mar; 43(3):134-5. PubMed ID: 23434355
[No Abstract] [Full Text] [Related]
17. An open-label pilot study to determine the efficacy of lopinavir/ritonavir and tenofovir DF in the treatment of HIV-infected patients experiencing first virologic failure on a non-nucleoside-based regimen.
Pierone G; Mieras J; Bulgin-Coleman D; Kantor C; Shearer J; Fontaine L; Fath M
AIDS Patient Care STDS; 2008 Apr; 22(4):263-6. PubMed ID: 18422459
[No Abstract] [Full Text] [Related]
18. Impact of tenofovir versus abacavir on HIV-related endothelial dysfunction.
Francisci D; Falcinelli E; Belfiori B; Petito E; Fierro T; Baldelli F; Gresele P
AIDS Patient Care STDS; 2011 Oct; 25(10):567-9. PubMed ID: 21851265
[No Abstract] [Full Text] [Related]
19. [Introduction. Tenofovir].
Mallolas J
Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():1. PubMed ID: 19195430
[No Abstract] [Full Text] [Related]
20. Tolerability of two different combinations of antiretroviral drugs including tenofovir used in occupational and nonoccupational postexposure prophylaxis for HIV.
Burty C; Prazuck T; Truchetet F; Christian B; Penalba C; Salmon-Ceron D; Yazdanpanah Y; May T; Rabaud C
AIDS Patient Care STDS; 2010 Jan; 24(1):1-3. PubMed ID: 20095911
[No Abstract] [Full Text] [Related]
[Next] [New Search]
